// App-Quantinova.ai

PB0045 : A pilot, open-label, phase II clinical trial of nebulised recombinant tissue-plasminogen activator in patients with COVID-19 acute respiratory distress syndrome: the PACA trial

Researchers

Presenter

  • P. Chowdary

Principal Investigators

  • B. Agarwal

  • M. Lipman

  • K. Gomez

Medical Centers

  • The Royal Marsden Hospital, London, United Kingdom

  • Department of Intensive care and Anaesthesia, Royal Free London NHS Foundation Trust, London, UK, London, England, United Kingdom

  • Department of Intensive care and Anaesthesia, Royal Free London NHS Foundation Trust, London, UK, London, England, United Kingdom

  • Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK and UCL Respiratory, University College London, London, UK, London, England, United Kingdom

  • Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK and Cancer Institute, University College London, London, UK, London, England, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Pulmonary/Respiratory Diseases

  • Infectious Diseases (ID)

Disease

  • Acute lung injury

  • Coronavirus disease

  • Pancreatic and cerebellar agenesis

Biomarkers

  • N/A

Drug/Treatment

  • Fibrinogen (IV)

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved